Life Sciences · Biotech · Active
First-in-class antibodies to restore the blood-brain barrier in neurological disease
Investment profile
The company
Lys Therapeutics develops first-in-class antibodies for neurodegenerative and neurovascular diseases. Its lead candidate, LYS241, blocks the harmful interaction between the enzyme tPA and NMDA receptors on blood vessel walls, an interaction that breaks down the blood-brain barrier and fuels neuroinflammation. Acting from within the blood vessels, it is being advanced towards the clinic in Parkinson's disease, multiple system atrophy and acute ischaemic stroke.
Related news
01 · Portfolio update · 22 March 2024
Lys Therapeutics announces the appointment of Michel Vounatsos, former Chief Executive Officer of Biogen, as Chairman of its Board of Directors.
Read the article02 · Portfolio update · 15 November 2022
Lys Therapeutics réunit 5,5 millions d'euros pour préparer les futures études cliniques de son anticorps monoclonal ciblant les pathologies neurovasculaires et neurodégénératives.
Read the article
